Product Description
Mechanisms of Action: AMPA Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: China | Italy | Korea | New Zealand | Portugal
Approved Indications: None
Known Adverse Events: None
Company: Nanjing Yoko Biomedical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Unknown Location
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Craniocerebral Trauma
Phase 1: Memory Disorders|Traumatic Brain Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NJYK-L-ORCT-III | P3 |
Recruiting |
Craniocerebral Trauma |
2024-08-30 |
66% |
| CTR20192202 | P1 |
Not yet recruiting |
Traumatic Brain Injury|Memory Disorders |
None |
|
| CTR20192539 | P3 |
Not yet recruiting |
Unknown |
None |